Cargando…

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different...

Descripción completa

Detalles Bibliográficos
Autores principales: Naranjo, Javier, Furlano, Mónica, Torres, Ferran, Hernandez, Jonathan, Pybus, Marc, Ejarque, Laia, Cordoba, Christian, Guirado, Lluis, Ars, Elisabet, Torra, Roser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050526/
https://www.ncbi.nlm.nih.gov/pubmed/35498884
http://dx.doi.org/10.1093/ckj/sfab293
_version_ 1784696386511437824
author Naranjo, Javier
Furlano, Mónica
Torres, Ferran
Hernandez, Jonathan
Pybus, Marc
Ejarque, Laia
Cordoba, Christian
Guirado, Lluis
Ars, Elisabet
Torra, Roser
author_facet Naranjo, Javier
Furlano, Mónica
Torres, Ferran
Hernandez, Jonathan
Pybus, Marc
Ejarque, Laia
Cordoba, Christian
Guirado, Lluis
Ars, Elisabet
Torra, Roser
author_sort Naranjo, Javier
collection PubMed
description BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. METHODS: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C–1E was assessed. RESULTS: A total of 118 patients were MC 1C–1E. The algorithm developed by the European Renal Association–European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C–1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of >16.5 cm before age 45 years has high specificity but low sensitivity. Assessing the MC by ultrasonography had high levels of agreement with magnetic resonance imaging (MRI) data, especially for 1A, 1D and 1E. The estimated glomerular filtration rate (eGFR) decline was very sensitive but had low specificity. In contrast, the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score was very specific but had poor sensitivity. Having hypertension before 35 years of age is a good clinical predictor of MC 1C–1E. Family history can be of help in suggesting RP, but by itself it lacks sufficient sensitivity and specificity. CONCLUSIONS: The MC by ultrasonography could be an option in hospitals with limited access to MRI as it performs well generally, and especially at the extremes of the MC, i.e. classes 1A, 1D and 1E. The eGFR decline is sensitive but not very specific when compared with the MC, whereas the PROPKD score is very specific but has low sensitivity. Integrating the different tools currently available to determine RP should facilitate the identification of rapid progressors among patients with ADPKD.
format Online
Article
Text
id pubmed-9050526
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90505262022-04-29 Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease Naranjo, Javier Furlano, Mónica Torres, Ferran Hernandez, Jonathan Pybus, Marc Ejarque, Laia Cordoba, Christian Guirado, Lluis Ars, Elisabet Torra, Roser Clin Kidney J Original Article BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and shows a wide phenotype. Only patients with rapid progression (RP) are included in clinical trials or are approved to receive disease-modifying drugs. This study aims at comparing different available predictive tools in ADPKD with the Mayo classification (MC) identification of rapid progressors based on high total kidney volume (TKV) according to age. METHODS: A total of 164 ADPKD patients were recruited retrospectively from a single centre. The performance of diverse tools to identify RP defined as being in MC categories 1C–1E was assessed. RESULTS: A total of 118 patients were MC 1C–1E. The algorithm developed by the European Renal Association–European Dialysis and Transplant Association Working Group on Inherited Kidney Disorders/European Renal Best Practice had a low sensitivity in identifying MC 1C–1E. The sensitivity and specificity of TKV to predict RP depend on the cut-off used. A kidney length of >16.5 cm before age 45 years has high specificity but low sensitivity. Assessing the MC by ultrasonography had high levels of agreement with magnetic resonance imaging (MRI) data, especially for 1A, 1D and 1E. The estimated glomerular filtration rate (eGFR) decline was very sensitive but had low specificity. In contrast, the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score was very specific but had poor sensitivity. Having hypertension before 35 years of age is a good clinical predictor of MC 1C–1E. Family history can be of help in suggesting RP, but by itself it lacks sufficient sensitivity and specificity. CONCLUSIONS: The MC by ultrasonography could be an option in hospitals with limited access to MRI as it performs well generally, and especially at the extremes of the MC, i.e. classes 1A, 1D and 1E. The eGFR decline is sensitive but not very specific when compared with the MC, whereas the PROPKD score is very specific but has low sensitivity. Integrating the different tools currently available to determine RP should facilitate the identification of rapid progressors among patients with ADPKD. Oxford University Press 2021-12-28 /pmc/articles/PMC9050526/ /pubmed/35498884 http://dx.doi.org/10.1093/ckj/sfab293 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Naranjo, Javier
Furlano, Mónica
Torres, Ferran
Hernandez, Jonathan
Pybus, Marc
Ejarque, Laia
Cordoba, Christian
Guirado, Lluis
Ars, Elisabet
Torra, Roser
Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title_full Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title_fullStr Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title_full_unstemmed Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title_short Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
title_sort comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050526/
https://www.ncbi.nlm.nih.gov/pubmed/35498884
http://dx.doi.org/10.1093/ckj/sfab293
work_keys_str_mv AT naranjojavier comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT furlanomonica comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT torresferran comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT hernandezjonathan comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT pybusmarc comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT ejarquelaia comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT cordobachristian comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT guiradolluis comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT arselisabet comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease
AT torraroser comparativeanalysisoftoolstopredictrapidprogressioninautosomaldominantpolycystickidneydisease